Understanding the New Alzheimer’s Treatment Landscape
For decades, families facing an Alzheimer’s diagnosis heard the same message: there is no cure, and treatment only masks symptoms. That chapter is closing. In 2026, two FDA-approved anti-amyloid medications are actively slowing cognitive decline in people with early-stage Alzheimer’s disease. These drugs do not reverse memory loss, but they target the underlying biology of the illness. Understanding how they work, who qualifies, and how to navigate US insurance coverage is the key to making informed decisions. This guide breaks down the facts, the costs, and the practical steps you need to know.
What the FDA Actually Approved
The US Food and Drug Administration has granted full approval to two intravenous (IV) therapies that clear amyloid-beta plaques from the brain. These plaques are a hallmark of Alzheimer’s and are linked to nerve cell damage. Both medications are designed for people in the earliest stages of the disease, when brain cells are still relatively healthy and can benefit from slowed progression.
Lecanemab (Brand Name: Leqembi)
Lecanemab received full FDA approval in 2023 after proving in large clinical trials that it significantly slowed cognitive decline by 27 percent over 18 months. Patients receive an IV infusion every two weeks. The drug requires regular brain scans to monitor for a known side effect called ARIA, which causes temporary brain swelling or tiny bleeds. Most patients tolerate the treatment well, but the monitoring schedule is strict. Doctors typically order baseline MRIs before the first dose, then repeat scans after the second, fourth, and seventh infusions, and periodically afterward.
Donanemab (Brand Name: Kisunla)
Donanemab gained full FDA approval in 2024 with a slightly different dosing approach. Patients receive monthly IV infusions for up to one year, or until scans show that amyloid plaques have cleared from the brain. Clinical data showed a 35 percent slowing of cognitive decline over 18 months for participants with early symptoms. Like lecanemab, donanemab requires frequent MRI monitoring. The treatment is generally stopped once plaque levels drop below a certain threshold, which can shorten the overall treatment timeline for some patients.
Key Takeaway: Both drugs are only approved for early-stage Alzheimer’s, which includes mild cognitive impairment or mild dementia. They are not recommended for moderate or severe stages, where amyloid plaques are no longer the primary driver of decline.
How Medicare and Private Insurance Cover These Drugs
Insurance coverage has been the biggest hurdle for patients seeking these therapies. In 2024, the Centers for Medicare & Medicaid Services (CMS) expanded coverage for both lecanemab and donanemab under Medicare Part B. This means traditional Medicare now pays for the drug itself, not just the infusion room fees. However, coverage comes with specific rules.
Medicare requires patients to enroll in a data collection registry, such as the Alzheimer’s Disease Diagnostic Centers (ADDC) network or the CMS-approved Alzheimer’s Disease Registry. This registry tracks treatment outcomes and safety data. Doctors must document that the patient has confirmed amyloid buildup through a PET brain scan or cerebrospinal fluid test. Without that confirmation, Medicare will deny the claim.
Private insurance companies have largely followed Medicare’s lead. Most major carriers cover both drugs when patients meet early-stage criteria and complete required prior authorization forms. Step therapy is rarely required for these medications, but network restrictions still apply. Patients must use in-network infusion centers and neurologists who are enrolled in the drug manufacturer’s patient support program. Always verify coverage details with your insurer before starting treatment, as plan rules can vary by state and policy type.
Real Costs for Patients in 2026
Even with insurance, the financial picture requires careful planning. The wholesale price of these medications remains high, but out-of-pocket costs depend heavily on your coverage type, deductible, and copay structure.
- Medication Costs: Lecanemab costs approximately $26,500 per year. Donanemab costs roughly $32,000 annually, though treatment may stop early once plaques clear.
- Infusion Fees: Clinic visits range from $500 to $1,500 per session. Medicare Part B covers 80 percent of the infusion cost after the annual deductible is met.
- MRI Monitoring: Brain scans are required every few months. Each scan costs between $1,000 and $2,000 out-of-pocket, depending on facility pricing and insurance network status.
- Total Annual Expense: Without assistance, total costs can exceed $40,000 per year. With Medicare Advantage plans, many patients cap their annual spending between $2,000 and $5,000. Traditional Medicare beneficiaries often face higher out-of-pocket costs unless they supplement with a Medigap policy or use manufacturer assistance programs.
Both drug manufacturers offer robust financial assistance programs. These programs cover copays, deductibles, and sometimes even travel costs to infusion centers. Eligibility usually depends on household income and insurance status. Patients should apply through the official patient support portals before their first appointment to avoid billing delays.
What You Need to Start Treatment
Starting therapy is a structured process that begins long before the first IV bag. Here is the step-by-step pathway most US clinics follow:
- Confirm the Diagnosis: A neurologist or geriatric specialist must verify early-stage Alzheimer’s through cognitive testing, medical history, and brain imaging.
- Get Amyloid Confirmation: Coverage requires proof of amyloid plaques. This comes from a PET scan or a lumbar puncture (spinal tap) to analyze cerebrospinal fluid.
- Complete a Baseline MRI: Doctors check for existing microbleeds, tumors, or structural abnormalities that could make treatment unsafe.
- Enroll in the Registry: Your clinic will register you in the FDA-approved data tracking program. This is mandatory for Medicare and most private insurers.
- Apply for Financial Assistance: Submit income verification and insurance details to the manufacturer’s support program. Approval typically takes 5 to 10 business days.
- Schedule Infusions: Treatment begins with a loading dose, followed by maintenance doses every two weeks (lecanemab) or monthly (donanemab). Each visit lasts 30 to 60 minutes.
Patients should plan for transportation, as driving is not recommended immediately after infusions due to potential dizziness or fatigue. Family members or medical transport services are often necessary. Infusion centers also provide detailed side effect guides, so patients know exactly what symptoms to report versus what is normal.
Looking Ahead: What to Expect in the Next Few Years
The Alzheimer’s treatment field is moving quickly. Researchers are testing oral pill versions of anti-amyloid drugs, which could eliminate IV visits entirely. Combination therapies that target both amyloid and tau proteins are also in late-stage clinical trials. Meanwhile, insurance coverage is becoming more standardized across states, and infusion center networks are expanding into rural areas. Early diagnosis remains the most powerful tool. If you notice memory changes in yourself or a loved one, request a comprehensive evaluation through a certified memory clinic. Time matters, and starting treatment in the earliest stage offers the best chance for meaningful results.
Conclusion
New Alzheimer’s drugs represent a major shift in how we approach brain health. They are not miracle cures, but they are the first treatments proven to slow disease progression when started early. Understanding FDA approval status, Medicare registry requirements, and real 2026 costs empowers patients and families to navigate the system with confidence. Work closely with a neurologist, verify insurance benefits upfront, and utilize manufacturer assistance programs to keep costs manageable. Early action, accurate diagnosis, and careful planning are the foundation of successful treatment. The landscape has changed, and staying informed is the best way to protect brain health moving forward.